New call-to-action
New call-to-action
New call-to-action

Foundation for Prader-Willi Blog | News

Categories

Expert Guidance Published for DCCR (VYKAT™ XR) Use in Prader-Willi Syndrome

An expert review, written by Drs. Miller, Shoemaker, Salehi, and Corletto, offers practical clinical guidance for the use of diazoxide choline extended-release (DCCR/VYKAT™ XR), the first FDA-approved treatment for hyperphagia in Prader-Willi syndrom...
May 11, 2026 Read More

Topics: News

FPWR Invests in ConSynance Therapeutics to Advance New Treatment for Prader-Willi Syndrome

The Foundation for Prader-Willi Research (FPWR) today announced a venture philanthropy investment in ConSynance Therapeutics, a clinical-stage biotechnology company developing CSTI-500, an investigational therapy for the treatment of behavioral dysre...
April 15, 2026 Read More

Topics: News

Top 10 Reasons to Attend the 2026 FPWR Prader-Willi Syndrome Conference in Philadelphia

Join us October 9–10 in Philadelphia for the annual FPWR Family Conference, a unique gathering dedicated to families and professionals affected by Prader-Willi syndrome. Over two powerful days, leading researchers, clinicians, and families from aroun...
March 18, 2026 Read More

Topics: News

New Study Opportunity for Prader-Willi Syndrome: Now Enrolling RM-718

A new clinical study is now enrolling individuals with Prader-Willi syndrome (PWS), offering families the opportunity to explore a potential new treatment for obesity and hyperphagia.
March 5, 2026 Read More

Topics: News, Clinical Trials Opportunities

Aardvark Therapeutics Announces Voluntary Pause of Hero Clinical Trial

SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the tr...
February 27, 2026 Read More

Topics: News

The Global PWS Registry: Turning Lived Experience Into Better Care

Families living with Prader-Willi syndrome are changing how PWS is understood, studied, and treated.
February 24, 2026 Read More

Topics: News, Research, Parents

The FPWR Therapeutic Accelerator Program: Bridging Research and Development

While much of FPWR’s work starts with discovery research, our mission extends across the full drug development pathway, supporting progress from foundational science all the way to potential treatments for Prader-Willi syndrome (PWS).
January 26, 2026 Read More

Topics: News

Pivotal Study Results of  VYKAT™ XR Published

Soleno Therapeutics has published results from its pivotal Phase 3 clinical study of VYKAT™ XR (diazoxide choline extended-release tablets, DCCR) in The Journal of Clinical Endocrinology and Metabolism, a peer-reviewed journal for endocrine and metab...
January 12, 2026 Read More

Topics: News

Your 2025 Impact: FPWR Fundraising Wrapped

Every breakthrough, every milestone, and every step forward in 2025 had one thing in common: our community. Because supporters like you showed up. You shared your story. You asked others to stand with you. And it mattered.
January 9, 2026 Read More

Topics: News

About FPWR

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax exempt status as a public charity under section 501(c)(3).

4star120x60

NORD_MembershipLogo_Platinum_2021

excellence-in-giving-logo

Main Menu

Our Mission

The mission of FPWR is to eliminate the challenges of Prader-Willi syndrome through the advancement of research and therapeutic development.

Contact Us

Foundation for Prader-Willi Research
Phone: 888-322-5487
Email: info@fpwr.org

FPWR
440 N Barranca Ave #3620
Covina, CA 91723

Copyright © 2020. All Rights Reserved. Terms of Use. Privacy Policy. Copyright Infringement Policy. Disclosure Statement.